纳米级造影剂在肿瘤影像学诊疗中的基础应用进展

doi:10.7517/issn.1674-0475.200818

摘要/Abstract

摘要： 肿瘤的早期诊断对其生存率及预后有极大的意义，医学成像造影剂的应用可极大地提高肿瘤的早期诊断水平。通过新兴纳米技术开发无毒、成像能力更强、循环时间更长的纳米级造影剂是目前研究的热点。本文综述了纳米级造影剂在MRI、CT、US、PET和SPECT等生物医学成像技术中，对于肿瘤诊疗的基础应用，并列举了部分研究实例。纳米级造影剂具有广阔的临床应用前景，未来的研究重点将会是开发集诊断、治疗于一体的多功能的纳米平台。

关键词: 纳米材料, 造影剂, 影像诊断, 肿瘤

Abstract: The early diagnosis of tumors, which is crucial to patients' survival rate and prognosis, can be greatly improved by the application of medical imaging contrast agents. The development of non-toxic nano-sized contrast agents with stronger imaging ability and longer cycling time through emerging nanotechnology is a hot topic in current research. Herein, the basic applications of such agents to tumor diagnosis of biomedical imaging technologies such as MRI, CT, US, PET and SPECT are summarized, together with some research examples. The nano-sized contrast agents are confirmed to have broad clinical application prospects. Moreover, the future research direction of developing a multi-functional nano-sized platform integrating diagnosis and treatment is proposed.

Key words: nanoparticle, contrast agent, imaging diagnosis, tumor

朱小琪, 刘军杰, 李红学, 周知展. 纳米级造影剂在肿瘤影像学诊疗中的基础应用进展[J]. 影像科学与光化学, 2021, 39(2): 159-165.

ZHU Xiaoqi, LIU Junjie, LI Hongxue, ZHOU Zhizhan. Advances in Basic Application of Nano-sized Contrast Agents to Imaging Diagnosis of Tumors[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(2): 159-165.

参考文献

[1] Sugumaran S, Jamlos M F, Ahmad M N, et al.Nanostructured materials with plasmonic nanobiosensors for early cancer detection:A past and future prospect[J].Biosensors & Bioelectronics,2018,100:361-373.
[2] Han X, Xu K, Taratula O, et al.Applications of nanoparticles in biomedical imaging[J].Nanoscale,2019,11(3):799-819.
[3] Kiessling F, Mertens M E, Grimm J, et al.Nanoparticles for imaging:top or flop?[J].Radiology,2014,273(1):10-28.
[4] Yang J, Han S, Zheng H, et al.Preparation and application of micro/nanoparticles based on natural polysaccharides[J].Carbohydrate Polymers,2015,123:53-66.
[5] Cormode D P, Jarzyna P A, Mulder W J, et al.Modified natural nanoparticles as contrast agents for medical imaging[J].Advanced Drug Delivery Reviews,2010,62(3):329-338.
[6] Chen Y, Chen H, Zeng D, et al.Core/shell structured hollow mesoporous nanocapsules:a potential platform for simultaneous cell imaging and anticancer drug delivery[J].ACS Nano,2010,4(10):6001-6013.
[7] Yang H, Cai W, Xu L, et al.Nanobubble-affibody:novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor[J].Biomaterials,2015,37:279-288.
[8] Tong X, Liu M, Zhang K, et al.Oligoethylenimine-grafted chitosan as enhanced T1 contrast agent for in vivo targeted tumor MRI[J].Journal of Magnetic Resonance Imaging,2016,44(1):23-29.
[9] Wang D, Yang K, Gao Y H, et al.Preparation and characterization of a nanoscale ultrasound contrast agent[J].Clinical Imaging,2010,34(4):288-292.
[10] Kohl Y, Kaiser C, Bost W, et al.Preparation and biological evaluation of multifunctional PLGA-nanoparticles designed for photoacoustic imaging[J].Nanomedicine,2011,7(2):228-237.
[11] Hu Y, Wang Y, Jiang J, et al.Preparation and characterization of novel perfluorooctyl bromide nanoparticle as ultrasound contrast agent via layer-by-layer self-assembly for folate-receptor-mediated tumor imaging[J].BioMed Research International,2016,2016:6381464.
[12] Zhang Z, Ross R D,Roeder R K.Preparation of functionalized gold nanoparticles as a targeted X-ray contrast agent for damaged bone tissue[J].Nanoscale,2010,2(4):582-586.
[13] Bhakta G, Sharma R K, Gupta N, et al.Multifunctional silica nanoparticles with potentials of imaging and gene delivery[J].Nanomedicine,2011,7(4):472-479.
[14] Li J, Wu C, Hou P, et al.One-pot preparation of hydrophilic manganese oxide nanoparticles as T(1) nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo[J].Biosensors & Bioelectronics,2018,102:1-8.
[15] Bardhan R, Lal S, Joshi A, et al.Theranostic nanoshells:from probe design to imaging and treatment of cancer[J].Accounts of Chemical Research,2011,44(10):936-946.
[16] Hamano N, Kamoshida S, Kikkawa Y, et al.Development of antibody-modified nanobubbles using Fc-region-binding polypeptides for ultrasound imaging[J].Pharmaceutics,2019,11(6):283.
[17] Grimm J and Scheinberg D A.Will nanotechnology influence targeted cancer therapy?[J].Seminars in Radiation Oncology,2011,21(2):80-87.
[18] Lai M H, Lee S, Smith C E, et al.Tailoring polymersome bilayer permeability improves enhanced permeability and retention effect for bioimaging[J].ACS Applied Materials & Interfaces,2014,6(13):10821-10829.
[19] Nitta N, Takakusagi Y, Kokuryo D, et al.Intratumoral evaluation of 3D microvasculature and nanoparticle distribution using a gadolinium-dendron modified nano-liposomal contrast agent with magnetic resonance micro-imaging[J].Nanomedicine,2018,14(4):1315-1324.
[20] Sulheim E, Kim J, van Wamel A, et al.Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models[J].Journal of Controlled Release,2018,279:292-305.
[21] Hoshyar N, Gray S, Han H, et al.The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction[J].Nanomedicine,2016,11(6):673-692.
[22] Rao J.Shedding light on tumors using nanoparticles[J].ACS Nano,2008,2(10):1984-1986.
[23] Das M, Duan W, Sahoo S K.Multifunctional nanoparticle-EpCAM aptamer bioconjugates:a paradigm for targeted drug delivery and imaging in cancer therapy[J].Nanomedicine,2015,11(2):379-389.
[24] Huang Y, He S, Cao W, et al.Biomedical nanomaterials for imaging-guided cancer therapy[J].Nanoscale,2012,4(20):6135-6149.
[25] Schleich N, Po C, Jacobs D, et al.Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy[J].Journal of Controlled Release,2014,194:82-91.
[26] Naseri N, Ajorlou E, Asghari F, et al.An update on nanoparticle-based contrast agents in medical imaging[J].Artificial Cells, Nanomedicine, and Biotechnology,2018,46(6):1111-1121.
[27] Zhu L, Zhou Z, Mao H, et al.Magnetic nanoparticles for precision oncology:theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy[J].Nanomedicine,2017,12(1):73-87.
[28] Chiang W H, Huang W C, Chang C W, et al.Functionalized polymersomes with outlayered polyelectrolyte gels for potential tumor-targeted delivery of multimodal therapies and MR imaging[J].Journal of Controlled Release,2013,168(3):280-288.
[29] Li Z, Hu Y, Miao Z, et al.Dual-stimuli responsive bismuth nanoraspberries for multimodal imaging and combined cancer therapy[J].Nano Letters,2018,18(11):6778-6788.
[30] Cai X, Zhu Q, Zeng Y, et al.Manganese oxide nanoparticles as MRI contrast agents in tumor multimodal imaging and therapy[J].International Journal of Nanomedicine,2019,14:8321-8344.
[31] Wang L, Huang J, Chen H, et al.Exerting enhanced permeability and retention effect driven delivery by ultrafine iron oxide nanoparticles with T(1)-T(2) switchable magnetic resonance imaging contrast[J].ACS Nano,2017,11(5):4582-4592.
[32] Kim H K, Lee G H, Chang Y.Gadolinium as an MRI contrast agent[J].Future Medicinal Chemistry,2018,10(6):639-661.
[33] Ittrich H, Peldschus K, Raabe N, et al.Superparamagnetic iron oxide nanoparticles in biomedicine:applications and developments in diagnostics and therapy[J].R Fo:Fortschritte auf dem Gebiete der R ntgenstrahlen und der Nuklearmedizin,2013,185(12):1149-1166.
[34] Anbazhagan R, Su Y A, Tsai H C, et al.MoS₂-Gd chelate magnetic nanomaterials with core-shell structure used as contrast agents in in vivo magnetic resonance imaging[J].ACS Applied Materials & Interfaces,2016,8(3):1827-1835.
[35] Cao Y, Zu G, Kuang Y, et al.Biodegradable nanoglobular magnetic resonance imaging contrast agent constructed with host-guest self-assembly for tumor-targeted imaging[J].ACS Applied Materials & Interfaces,2018,10(32):26906-26916.
[36] Xiong F, Hu K, Yu H, et al.A functional iron oxide nanoparticles modified with PLA-PEG-DG as tumor-targeted MRI contrast agent[J].Pharmaceutical Research,2017,34(8):1683-1692.
[37] Gao J, Li L, Liu X, et al.Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer[J].Experimental and Therapeutic Medicine,2018,15(6):5415-5421.
[38] Mi P, Kokuryo D, Cabral H, et al.A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy[J].Nature Nanotechnology,2016,11(8):724-730.
[39] Zhang C, Moonshi S S, Wang W, et al.High F-content perfluoropolyether-based nanoparticles for targeted detection of breast cancer by (19)F magnetic resonance and optical imaging[J].ACS Nano,2018,12(9):9162-9176.
[40] Li H, Gan S, Feng S T, et al.Nano-sized ultrasound contrast agents for cancer therapy and theranostics[J].Current Pharmaceutical Design,2017,23(35):5403-5412.
[41] Chen Y L, Liu F Q, Guo Y, et al.PA/US dual-modality imaging to guide VEGFR-2 targeted photothermal therapy using ZnPc-/PFH-loaded polymeric nanoparticles[J].Biomaterials Science,2018,6(8):2130-2143.
[42] Zhang X, Zheng Y, Wang Z, et al.Methotrexate-loaded PLGA nanobubbles for ultrasound imaging and Synergistic Targeted therapy of residual tumor during HIFU ablation[J].Biomaterials,2014,35(19):5148-5161.
[43] Singh P, Pandit S, Mokkapati V, et al.Gold nanoparticles in diagnostics and therapeutics for human cancer[J].International Journal of Molecular Sciences,2018,19(7):1979.
[44] Ghaghada K B, Badea C T, Karumbaiah L, et al.Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging[J].Academic Radiology,2011,18(1):20-30.
[45] Lee N, Choi S H, Hyeon T.Nano-sized CT contrast agents[J].Advanced Materials,2013,25(19):2641-2660.
[46] Zou Y, Wei Y, Sun Y, et al.Cyclic RGD-functionalized and disulfide-crosslinked iodine-rich polymersomes as a robust and smart theranostic agent for targeted CT imaging and chemotherapy of tumor[J].Theranostics,2019,9(26):8061-8072.
[47] Hu X, Sun J, Li F, et al.Renal-clearable hollow bismuth subcarbonate nanotubes for tumor targeted computed tomography imaging and chemoradiotherapy[J].Nano Letters,2018,18(2):1196-1204.
[48] Kim D, Jeong Y Y, Jon S.A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer[J].ACS Nano,2010,4(7):3689-3696.
[49] Wang X, Wang J, Pan J, et al.Rhenium sulfide nanoparticles as a biosafe spectral CT contrast agent for gastrointestinal tract imaging and tumor theranostics in vivo[J].ACS Applied Materials & Interfaces,2019,11(37):33650-33658.
[50] Kim J, Chhour P, Hsu J, et al.Use of nanoparticle contrast agents for cell tracking with computed tomography[J].Bioconjugate Chemistry,2017,28(6):1581-1597.
[51] Sun N, Zhao L, Zhu J, et al.(131)I-labeled polyethylenimine-entrapped gold nanoparticles for targeted tumor SPECT/CT imaging and radionuclide therapy[J].International Journal of Nanomedicine,2019,14:4367-4381.
[52] Mojarrad P, Zamani S, Seyedhamzeh M, et al.Novel radiopharmaceutical (technetium-99m)-(DOTA-NHS-ester)-methionine as a SPECT-CT tumor imaging agent[J].European Journal of Pharmaceutical Sciences,2020,141:105112.
[53] Hainfeld J F, Smilowitz H M, O'Connor M J, et al.Gold nanoparticle imaging and radiotherapy of brain tumors in mice[J].Nanomedicine,2013,8(10):1601-1609.
[54] Ventola C L.Progress in nanomedicine:approved and investigational nanodrugs[J].P & T,2017,42(12):742-755.